- Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity
-
Malaria persists as one of the most devastating global infectious diseases. The pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) has been identified as a new malaria drug target, and a triazolopyrimidine-based DHODH inhibitor 1 (DSM265) is in clinical development. We sought to identify compounds with higher potency against Plasmodium DHODH while showing greater selectivity toward animal DHODHs. Herein we describe a series of novel triazolopyrimidines wherein the p-SF5-aniline was replaced with substituted 1,2,3,4-tetrahydro-2-naphthyl or 2-indanyl amines. These compounds showed strong species selectivity, and several highly potent tetrahydro-2-naphthyl derivatives were identified. Compounds with halogen substitutions displayed sustained plasma levels after oral dosing in rodents leading to efficacy in the P. falciparum SCID mouse malaria model. These data suggest that tetrahydro-2-naphthyl derivatives have the potential to be efficacious for the treatment of malaria, but due to higher metabolic clearance than 1, they most likely would need to be part of a multidose regimen.
- Kokkonda, Sreekanth,Deng, Xiaoyi,White, Karen L.,Coteron, Jose M.,Marco, Maria,De Las Heras, Laura,White, John,El Mazouni, Farah,Tomchick, Diana R.,Manjalanagara, Krishne,Rudra, Kakali Rani,Chen, Gong,Morizzi, Julia,Ryan, Eileen,Kaminsky, Werner,Leroy, Didier,Martínez-Martínez, María Santos,Jimenez-Diaz, Maria Belen,Bazaga, Santiago Ferrer,Angulo-Barturen, I?igo,Waterson, David,Burrows, Jeremy N.,Matthews, Dave,Charman, Susan A.,Phillips, Margaret A.,Rathod, Pradipsinh K.
-
supporting information
p. 5416 - 5431
(2016/07/06)
-
- AMINOINDAN DERIVATIVE OR SALT THEREOF
-
Provided is a compound that is an NMDA receptor antagonist having a broader safety margin, and is useful as an agent for treating or preventing Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, or pain. A novel compound or a salt thereof, which is characterized in that it has an amino group and R1(lower alkyl, cycloalkyl, -lower alkylene-aryl, aryl which may be substituted, and the like) on carbon atoms of indane, cyclopenta[b]thiophene, cyclopenta[b]furan, cyclopenta[b]pyridine, or cyclopenta[c]pyridine ring, or 2,3-dihydrdo-1-benzofuran, 2,3-dihydrdo-1-benzothiophene, indoline ring, or the like, and has R2 and R3 (the same or different, each lower alkyl or aryl) on carbon atoms beside them, and an NMDA receptor antagonist comprising the same as an active component.
- -
-
Page/Page column 13
(2009/04/23)
-